Tissue-type plasminogen activator (t-PA) is expressed by vascular endothelial cells, where it is an essential factor in the removal of intravascular thrombi, and in brain tissue, where it is expressed in the hippocampus (1) and plays a role in neuronal plasticity (2). For full activity, t-PA requires a cofactor, such as fibrin, that increases the rate of plasminogen activation by t-PA by several orders of magnitude (3, 4). The fibrin-specificity of t-PA in a plasma environment is limited, because fibrinogen may also function as an, albeit much less efficient, cofactor. A higher fibrin-specificity was observed for naturally occurring, t-PA-like, PAs in the saliva of the vampire bat (D. rotundus), called DSPA-α1 and DSPA-α2 (5, 6).
fatal intracerebral hemorrhage (7) . A t-PA-induced higher vascular permeability may contribute to intracerebral hemorrhage. Plasmin that is locally generated by t-PA activates MMP-2, whereas t-PA directly increases the expression of MMP-9 by brain endothelial cells, via a plasmin-independent mechanism (8, 9) . The local increase in MMP-and plasmin-activities leads to the degradation of brain microvessels and contributes to the thrombolysis-associated hemorrhage (10) (11) (12) . This then may lead to the influx into the brain of plasma proteins, including t-PA, plasminogen and fibrinogen. Within the brain, t-PA promotes excitotoxin-induced neuronal degradation (13, 14) , most likely by inducing plasmin-mediated laminin degradation (15) . Unlike t-PA, DSPA infusion, at equivalent fibrinolytic dosages, did not enhance excitotoxin-mediated neurotoxicity (16) . An attractive hypothesis to explain the difference between DSPA and t-PA is that the cofactor requirements of DSPA are more stringent than for t-PA.
Amyloid beta peptide analogues markedly enhance plasminogen activation by t-PA, comparable to that of known stimulators of t-PA such as fibrin and fibrinogen (17) (18) (19) and are known to accumulate in amyloid plaques and in cerebral vessel walls of the elderly. Accumulation of amyloid beta in amyloid plaques and cerebral vessel walls is the hallmark of Alzheimer's Disease (AD), a neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly (20, 21) . Amyloid precursor protein is a type I membrane-spanning protein of 770 residues that releases its large ectodomain after at least two types of proteolytic cleavages. The site most frequently cut is at residue 687, which lies within the amyloid peptide and therefore prevents its formation (22) . A small percentage of APP is cleaved at residue 672 of APP by an activity dubbed β-secretase. This represents the first step in Alzheimer's-type amyloidogenesis. The β-secretase cleavage sets the stage for the next cleavage by an activity referred to as γ-secretase. The amyloid peptide is released after cleavage by the γ-secretase either between residues 40 and 41 or between residues 42 and 43. Polymerization of amyloid beta and subsequent neuronal deposition leads to the degeneration of neurons involved in memory and cognition. Mutations in the APP gene cause some forms of familial AD by favouring the formation of increased amounts of Aβ. The deposition of amyloid beta peptides in the brain vessel wall (23) may be relevant in the pathogenesis of hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D) and cerebral amyloid angiopathy-related cerebral hemorrhage (24) . It may also contribute to intracerebral hemorrhage that is a life-threatening complication in patients undergoing t-PA treatment for acute myocardial infarction or stroke.
In the present study we determined the potency of amyloid beta (1-42) as a cofactor for the activation of plasminogen by human t-PA and DSPA. We observed that Aβ1-42 is fifteen-fold less potent as a cofactor for plasminogen activation by DSPA than by t-PA. This difference may contribute to the lower excitotoxin-induced neuronal degradation after DSPA infusion into the brain if compared to t-PA.
Materials and methods
Recombinant t-PA (Actilyse ® ) was obtained from Boehringer Ingelheim (Biberach an der Riss, Germany) and DSPA-α1 from Paion GmbH (Aachen, Germany). Both PA preparations were dissolved in sterile water to a final concentration of 1 mg mL -1 . Glu-plasminogen was purified from human plasma on lysineSepharose and dissolved in plasma clot lysis assay (PCLA) buffer {PCLA buffer : NaCl (100 mM), NaHCO 3 (30 mM), 4 KCl (4 mM), CaCl 2 (1 mM), Na 2 HPO 4 (1 mM), MgCl 2 , (0.3 mM), MgSO 4 (0.4 mM), HEPES (20 mM), polysorbate 80 (0.01%), pH 7.4} (25) to 24 µM. Fibrinogen, essentially plasminogenfree (Sigma, St. Louis, USA), was dissolved in PCLA buffer to 1 mg mL -1 . Human thrombin (Sigma) was dissolved in PCLA buffer to 10 U mL -1 . The chromogenic substrate FlavigenPli (D-But-CHT-Lys-p-nitroanilide-diHCl) (Biopool, Umeå, Sweden) was dissolved in PCLA buffer to 2 mM. Aβ1-42 (Bachem, Basel, Switzerland) was dissolved in 0.1% NH 4 OH to a concentration of 1 mg mL -1 . All reagents were divided in aliquots and stored at -20°C for not more than 2 weeks until use. Thawed aliquots were used immediately and not frozen again.
Plasminogen activator assay
The PA assay was performed in microtiter plates in a total volume of 0.15 mL as previously described (6) . The order of addition of reagents was: 50 µL of plasminogen (0 to 24 µM); 15 µl of cofactor (1 mg mL -1 ); 10 µl of PA 7.5 nM and 75 µl of Flavigen-Pli (2mM). The final concentrations were: Plasminogen activator (t-PA or DSPA): 0.5 nM; Glu-plasminogen: 0.0625, 0.125, 0.25, 0.5, 1, 2, 4 and 8 µM; Flavigen-Pli: 1 mM and cofactors: 100 µg mL -1 . The following cofactors were compared to a control without cofactor: Aβ1-42, fibrinogen or fibrin. For the latter, the reaction mixture contained in addition 0.13 units/ml of human thrombin. Immediately after pipetting, the microtiter plate was introduced in a Molecular Device ThermoMax micro plate reader, set at 25°C. Mixing was done at time 0 sec. At regular intervals OD values were measured at 405 nm and 490 nm. The OD values at 490 nm were subtracted from the OD values at 405 nm to correct for changes in turbidity. In the remainder of the article OD = OD 405 -OD 490 . All assays were done in triplicate for each combination of plasminogen concentration, cofactor and PA and were repeated at least 3 times.
Mathematical analysis of the data
The following equations were used: The Michaelis-Menten equation for the conversion of chromogenic substrate into para-nitro-anilide (pNA). dpNA/dt = ks.pli.S/(Ks + S)
(1) Equation (1) can be simplified provided that throughout the experiments S > Ks dpNA/dt = ks.pli (1a) The Michaelis-Menten equation for the generation of plasmin. dpli/dt = kcat.PA.P/(Km + P) (2) Integration of this equation results in: pli = pli 0 + kcat.PA.P/(Km + P).t (3) Combination of (1a) and (3) gives: dpNA/dt = ks.pli 0 + ks.kcat.PA.P/(Km + P).t (4) Integration of this equation results in: pNA = pNA 0 + ks.pli 0 .t + 0.5*ks.kcat.PA.P/(Km + P).t 2 (5) OD = pNA.E (6) combination of (5) and (6) gives: OD (t) = pNA 0 .E + ks.pli 0 .E.t + 0.5*ks.kcat.PA.P/ (Km + P).E.t 2 (7) or: OD (t) = a.t 2 + b.t + c (8) Where a = 0.5*ks.kcat.PA.E.P/(Km + P) or a = z. P/(Km + P) (with z = 0.5*ks.kcat.PA.E) (9) b = ks.pli 0 .E; and c = pNA 0 .E Parabolic curve fitting of the experimental data of OD versus time allows to determine the values for a for each concentration of plasminogen. Plotting a versus P allows to calculate the values of kcat and Km by non-linear regression curve fitting of the data points to the Michaelis Menten equation. Calculations were performed on a Macintosh iMac 7300 using the Deltagraph program.
Abbreviations in the equations: S 0 and S = concentration of the substrate Flavigen-Pli at time 0 and t; P = concentration of plasminogen; pli 0 and pli = concentration of plasmin at time 0 and t; PA = concentration of plasminogen activator. ks and Ks = rate constant and Michaelis-Menten constant for the conversion of Flavigen-Pli by plasmin. kcat and Km = rate constant and Michaelis-Menten constant for the conversion of plasminogen by t-PA or DSPA. E = molar extinction coefficient for pNA in the configuration of the ELISA reader.
Results

Determination of the kinetic parameters for substrate conversion by plasmin
In preliminary experiments we determined the value for the molar absorbance of pNA (E) in our ELISA reader by fully converting Flavigen-Pli into pNA. Various Flavigen-Pli substrate concentrations were incubated for 2h with a high concentration of plasmin (100 nM). We verified that for each substrate concentration a plateau of OD had been reached. From these data the molar absorbance of pNA was calculated to be 2.98.10 3 OD.M -1 .
To determine the kinetic parameters (ks and Ks) for the conversion of Flavigen-Pli into pNA, various substrate concentrations (16 to 1000 µM) were incubated with plasmin and OD values determined at different times ( Fig. 1 left panel) . Nonlinear regression analysis of the initial substrate conversion rates vs. By nonlinear regression analysis of the initial substrate conversion rates vs. substrate concentrations the rate constant ks was calculated to be 1.36 s -1 , while the Michaelis-Menten constant Ks was calculated to be 88.1 µM.
substrate concentrations (Fig. 1 right panel) according to the Michaelis-Menten equation enabled us to calculate ks and Ks. The rate constant ks was calculated to be 1.36 s -1 , while the Michaelis-Menten constant Ks was calculated to be 88.1 µM. Based upon the value of Ks we decided to perform the subsequent kinetic experiments at a substrate concentration of 1000 µM and to limit the kinetic analyses to OD values below 1.5. Under these conditions, substrate concentrations were always at least six times greater than the Ks value and we may therefore ignore the effect of plasmin substrate depletion on reaction rates.
Effect of cofactors on the activation of glu-plasminogen by t-PA or DSPA
We made a dose response curve for Aβ1-42 as cofactor for the activation of plasminogen by DSPA or t-PA. For both PAs highest cofactor activities were obtained for 100 µg/ml of Aβ1-42 (Fig. 2) . This concentration of Aβ1-42 was the highest achievable, because, according to the manufacturers instructions, the peptide had to be dissolved to a concentration of 1 mg mL -1 in 0.1% NH 4 OH and at higher peptide concentrations the peptide solvent would have modified the plasminogen activation conditions. The remainder of the comparative studies was, therefore, done at cofactor concentrations of 100 µg mL -1 .
We incubated various concentrations of plasminogen (from 0.0625 to 8 µM) with t-PA or DSPA (at 0.5 nM) in the presence of buffer or 100 µg mL -1 of the cofactors Aβ1-42, fibrinogen or fibrin. The rate of plasmin generation, as derived from the conversion of chromogenic substrate was comparable for t-PA and DSPA when fibrin was used as a cofactor. In striking contrast, activation rates by t-PA were much higher than those by DSPA for Aβ1-42 or fibrinogen as cofactors or in the presence of buffer alone (see below). At the physiological plasminogen concentration of 2 µM, the plasmin generation curves were linear both for t-PA and DSPA, with 100 µg mL -1 of Aβ1-42 (Fig. 3) , as well as with fibrinogen and fibrin as cofactor (data not shown). Figure 4 shows for each cofactor-PA-plasminogen concentration combination the curve of incubation time versus OD405-490 that served as the basis for the calculation of the reaction rate parameters. (N.B for each experimental condition only the "middle" curve of three is shown). In agreement with the theoretical model (see equation 7) a good fit (r^2 values in general well above 0.99) was observed with second order polynomial curves: OD (t) = a.t 2 + b.t + c. Nonlinear regression analysis of the 2nd order polynomial plots of OD versus time (see equations 8 and 9) enabled us to calculate, for each [plasminogen], cofactor and PA combination, the value of a {= 0.5*ks.kcat.PA.E.P/(Km + P)}. The results of a vs. [plasminogen] are plotted in Figure 5 . From these curves the values for kcat and Km can be derived separately by non-linear regression analysis using the Michaelis-Menten equation. An essential requirement for such an analysis is that the highest plasminogen concentrations used are much higher than Km (ideally 10 ϫ Km). A first analysis of curves from Fig. 5 shows that this requirement is only met for the conditions DSPA with Aβ1-42, fibrinogen or fibrin as cofactors and for t-PA only with fibrin as cofactor. For the other conditions only the ratio kcat/Km can be reliably calculated (Table 1) .
The derivation of the kinetic constants as such is not sufficient to compare the efficacies of the various cofactors under physiological conditions, because the reaction rates at plasminogen concentrations close to or below the Km are highly dependent on the plasminogen concentrations. For this reason, we calculated the reaction rates at the physiological concentrations of plasminogen in plasma (2 µM), using the MichaelisMenten equation. From this we then calculated the relative efficacies of the various cofactors for the activation of plasminogen by t-PA or DSPA ( Table 2 ). The results show that in the presence of fibrin and 2 µM of plasminogen, DSPA and t-PA have the same activity, whereas without cofactor DSPA is 83 times less active than t-PA. In the presence of the cofactors Aβ1-42 and fibrinogen at the physiological plasminogen concentration of 2 µM, DSPA was found to be 15 and 18-fold, respectively, less active than t-PA.
Discussion
We made a comparative analysis of the potency of Aβ1-42 (as well as of fibrinogen and fibrin) as a cofactor for the activation 565 Table 2 : Relative rates of plasminogen activation at the physiological plasminogen concentration of 2 µM calculated from the kinetic parameters given in Table 1 . The reaction rate for DSPAα1-control without cofactor is set at 1. of plasminogen by human t-PA and DSPAα1. We observed that, under conditions of physiological plasminogen concentrations (2 µM) DSPA was equally active as t-PA when fibrin was present as a cofactor, but two orders of magnitude less active without cofactor. In the presence of Aβ1-42 as cofactor, the activity of DSPA was comparable to that with fibrinogen as cofactor and 16-fold less active than t-PA in the presence of either of these cofactors. The results for fibrinogen or fibrin as cofactor for DSPA or t-PA are comparable to those previously reported (6) .
One limitation of the present study, as well as of a previous study (6) is that for certain experimental conditions the highest plasminogen concentrations used was much lower than the estimated Km value, whereas ideally the highest plasminogen concentrations should have been tenfold higher. Thus for t-PA without cofactor or with fibrinogen or Aβ1-42 as cofactors and for DSPA without cofactor we could only determine the ratio kcat/Km. Nevertheless, the data for DSPA clearly show that the three cofactors induce an, at least tenfold, decrease in Km value, whereas the higher cofactor efficacy of fibrin, as compared to that of fibrinogen or Aβ1-42 was mainly due to a very strong increase in kcat values. Km values for fibrin as cofactor were similar to that for Aβ1-42 and twofold lower than that for fibrinogen. In contrast to our results, a previous report observed a forty-fold lower Km with fibrin as cofactor as compared to fibrinogen (6) .
We observed a clear dose effect of Aβ1-42 as cofactor for plasminogen activation by t-PA or DSPA, with highest activities obtained at 100 µg/ml of Aβ1-42 (i.e. the highest concentration of Ab1-42 that could be attained under our experimental conditions) (Fig. 2) . In contrast to our results, Wnendt et al. (18) observed that cofactor activity for t-PA was higher with Aβ1-42 at 10 µg/ml than at 100 µg/ml. The experimental approach of the two studies was quite similar, except the composition of the assay buffer and the peptide solvent. At present we can only speculate, whether the difference in cofactor behaviour is due to the difference in peptide solvent or the buffer composition. A time-dependent increase in cofactor activity of Aβ1-40 was observed, which was due to a plasmin-mediated cleavage of Aβ1-40 between arg5 and his6 (26) . The increased cofactor activity of the cleaved Aβ1-40 peptide represents a positive feedback mechanism that may amplify local proteolytic activity. In contrast, we observed no time-dependent increase in the rate of plasmin generation when Aβ1-42 was used as a cofactor (Fig. 3) . Most likely the difference is due to the presence in our study of a chromogenic plasmin substrate that acts as a competitive plasmin inhibitor, and is expected to reduce plasmin activity by over 90%.
During thrombolytic therapy of stroke, t-PA may exert two pathogenic side effects, induction of cerebral hemorrhage, by degrading the blood vessel wall, and stimulating neuronal degeneration (13, 14) , most likely due to a plasmin-mediated degradation of laminin (15) . Possible cofactors that may be relevant for the development of complications of thrombolytic therapy of stroke are Aβ1-42 and fibrinogen. In elderly patients, Aβ1-42 may be present as deposits in the cerebrovascular wall or as amyloid plaques in the brain, whereas fibrinogen may penetrate into the brain as a consequence of intracerebral hemorrhage. Our observation that Aβ1-42, like fibrinogen, is a less efficient cofactor for DSPA than for t-PA may offer an explanation for the finding that intracerebral infusion of t-PA, leads to excitotoxin-induced neuronal degradation whereas equivalent amounts of DSPA had no pathogenic effect (16) .
Taken together our data show that DSPA is much less active than t-PA in the presence of the cofactors fibrinogen or Aβ1-42. In the context of treatment of stroke this may lead to a lower proteolytic activity in regions where fibrin is absent. To what extent this would result in a higher therapeutic efficacy or reduced incidence of complications can only be established in appropriately designed animal or clinical studies.
